Using targeted radiation to improve CAR T cell therapy for neuroblastoma in children
Official title: Targeted Radionuclide Therapy to Enhance the Efficacy of CAR T Cells Against Neuroblastoma
Funded at University of Wisconsin-Madison · NIH-10985352 · Data updated 2026-11-12
This study is looking at a new way to make CAR T cell therapy work better for kids with neuroblastoma by adding a special low-dose treatment that helps the CAR T cells target and destroy the tumors more effectively.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $159,636 |
| NIH project number | 1K08CA285941-01A1 |
| Project ID | NIH-10985352 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children aged 0-11 years diagnosed with neuroblastoma.
✕Less likely to help
Patients with neuroblastoma who are not eligible for CAR T cell therapy or those with advanced-stage disease may not benefit from this research.
What this research studies
This research focuses on enhancing the effectiveness of CAR T cell therapy, a type of immunotherapy, by combining it with low-dose targeted radionuclide therapy (TRT) specifically for treating neuroblastoma in children. The approach aims to sensitize tumors, making them more susceptible to destruction by CAR T cells. The research is being conducted by Dr. Quaovi Sodji at the University of Wisconsin-Madison, who is receiving mentorship from experts in immunology and radionuclide therapy. The project includes training in tumor immunology, radiochemistry, and laboratory management to ensure a comprehensive understanding of the treatment mechanisms.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for children with neuroblastoma, potentially improving survival rates and quality of life.
How similar studies have gone: Previous research has shown promising results in combining immunotherapy with targeted radiation, suggesting that this approach could be effective for treating neuroblastoma.
Where this research is happening
-
University of Wisconsin-Madison
Madison, United States Active
Researchers
- Principal investigator: Sodji, Quaovi H — University of Wisconsin-Madison
- Study coordinator: Sodji, Quaovi H
Related research
Other NIH-funded projects on the same topics.
-
Computational and functional screens to find actionable neuroblastoma drivers
Researchers are using advanced computer analysis and lab tests to find new genes and drug targets in neuroblastoma, aiming to improve outcomes for children.
-
Understanding ATRX in neuroblastoma: new protein functions and treatment clues
A short, patient-friendly look at a study exploring how altered ATRX proteins in neuroblastoma might influence disease behavior and response to therapy.
-
Neuroblastoma and radiopharmaceuticals: understanding how targeted radiation affects kids’ tumors
A pediatric cancer grant studies how a targeted radiotherapy called 131I-MIBG affects tumor and surrounding cells in children with high-risk neuroblastoma.
-
Bispecific antibodies to help kids fight neuroblastoma and brain tumors
A pediatric-focused grant tests new bispecific antibodies that help the immune system attack childhood cancers like neuroblastoma and brain tumors.
-
ADEPT-STAR therapy for high risk neuroblastoma
A new cell-based therapy approach aims to help children with high-risk neuroblastoma by using off-the-shelf, donor-derived treatments.
-
MYCN and ferroptosis: a new vulnerability in pediatric neuroblastoma
A study in children with neuroblastoma looks at a new vulnerability called ferroptosis that could be exploited to more effectively treat tumors with the MYCN gene amplification.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.